Nearly 6,600 patients have been registered in the Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study. More than 5,000 positron emission tomography (PET) scans have already been completed as part of the study at more than 700 active sites nationwide.
The $100 million study will determine the clinical usefulness on patient-oriented outcomes of a brain PET scan that detects amyloid plaques, a core feature of Alzheimer’s disease. In addition to assessing the impact of amyloid PET on management of patients with mild cognitive impairment or dementia of uncertain cause, the study will compare outcomes for study participants with a matched cohort that is not in the study.
This research will inform future Centers for Medicare & Medicaid payment decisions regarding PET scans in dementia care. Personnel from active IDEAS sites and those interested in the study can attend a session January 20 at 7am (Noble Room, 8000 S) at the upcoming SNMMI Mid-Winter Meeting in Phoenix, AZ.
The IDEAS Study is directed by the Alzheimer’s Association and sponsored by the American College of Radiology Imaging Network (ACRIN®).
For more information on the IDEAS Study, visit Ideas-Study.org.